Observations placeholder

Certolizumab pegol and Cimzia

Identifier

017733

Type of Spiritual Experience

Hallucination

Number of hallucinations: 12

Background

A description of the experience

Certolizumab pegol  (CDP870, tradename Cimzia) is a therapeutic monoclonal antibody to tumor necrosis factor alpha (TNF-α), for the treatment of Crohn's disease and rheumatoid arthritis.

On Jan, 18, 2017 23,550 people reported to have side effects when taking Cimzia.   Among them, 12 people (0.05%) have Hallucination

Time on Cimzia when people have Hallucination  :

  < 1 month 1 - 6 months 6 - 12 months 1 - 2 years 2 - 5 years 5 - 10 years 10+ years
Hallucination 0.00% 50.00% 0.00% 0.00% 50.00% 0.00% 0.00%

Gender of people who have Hallucination when taking Cimzia  :

  Female Male
Hallucination 25.00% 75.00%

Age of people who have Hallucination when taking Cimzia  :

  0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Hallucination 0.00% 0.00% 0.00% 25.00% 0.00% 0.00% 0.00% 75.00%

The source of the experience

eHealthme

Concepts, symbols and science items

Concepts

Symbols

Science Items

TNFs

Activities and commonsteps

Commonsteps

References